{"id":49878,"title":"Efficacy and safety of endovascular arteriovenous fistula creation with comparison to surgically created fistulas: a systematic review and meta-analysis protocol","title_html":"<p>Efficacy and safety of endovascular arteriovenous fistula creation with comparison to surgically created fistulas: a systematic review and meta-analysis protocol<\/p>","image":{"source":"https:\/\/s3.amazonaws.com\/protocols-files\/files\/dimybj75p.jpg","placeholder":"https:\/\/s3.amazonaws.com\/protocols-files\/files\/dimybj75p.jpg"},"doi":"dx.doi.org\/10.17504\/protocols.io.buxwnxpe","doi_status":2,"uri":"efficacy-and-safety-of-endovascular-arteriovenous-buxwnxpe","type_id":1,"template_id":1,"published_on":1620910302,"parent_protocols":[],"parent_collections":[],"cited_protocols":[],"version_id":0,"version_data":{"id":"0","code":"buxwnxpe","parent_id":0,"parent_uri":null,"is_same_owner":false,"has_pending_merge_request":false,"has_approved_merge_request":false},"created_on":1620790204,"modified_on":null,"categories":null,"public":1,"is_unlisted":0,"creator":{"name":"Yoshinosuke Shimamura","affiliation":"Teine Keijinkai Medical Center","affiliations":[{"affiliation":"Teine Keijinkai Medical Center","url":"","is_default":1}],"username":"m4wle1x1x1x4wle1","note":null,"link":null,"image":{"source":"\/img\/avatars\/002.png","placeholder":"\/img\/avatars\/002.png"},"badges":[{"id":2,"image":{"source":"\/img\/badges\/bronze.svg","placeholder":"\/img\/badges\/bronze.svg"},"name":"Author"}],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"journal":null,"journal_name":null,"journal_link":null,"article_citation":null,"has_versions":0,"link":null,"total_collections":0,"number_of_steps":21,"authors":[{"name":"Yoshinosuke Shimamura","affiliation":"Department of Nephrology, Teine Keijinkai Medical Center, Sapporo, Hokkaido, Japan","affiliations":[],"username":"m4wle1x1x1x4wle1","note":"Corresponding author","link":null,"image":{"source":"\/img\/avatars\/002.png","placeholder":"\/img\/avatars\/002.png"},"badges":[],"verified":1,"is_verified_user":true,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Yasutaka Kuniyoshi","affiliation":"Tsugaruhoken Medical COOP Kensei Hospital","affiliations":[],"username":"m4tle1z1s1y4ule1","note":"Systematic Review Workshop Peer Support Group (SRWS-PSG), Osaka, Japan","link":null,"image":{"source":"\/img\/avatars\/005.png","placeholder":"\/img\/avatars\/005.png"},"badges":[],"verified":1,"is_verified_user":true,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Hajime Yamazaki","affiliation":"Department of Community Medicine, Graduate School of Medicine, Kyoto University, Sakyo, Kyoto, Japan","affiliations":[],"username":null,"note":"","link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Yasushi Tsujimoto","affiliation":"Department of Nephrology and Dialysis, Kyoritsu Hospital, Kawanishi, Hyogo, Japan","affiliations":[],"username":"m4vle102u1s4wle1","note":"Systematic Review Workshop Peer Support Group (SRWS-PSG), Osaka, Japan","link":null,"image":{"source":"\/img\/avatars\/015.png","placeholder":"\/img\/avatars\/015.png"},"badges":[],"verified":1,"is_verified_user":true,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false}],"versions":[],"groups":[{"id":24879,"uri":"shimamura-y","title":"Shimamura Y","image":{"source":"https:\/\/www.protocols.io\/img\/group_placeholder.png","placeholder":"https:\/\/www.protocols.io\/img\/group_placeholder.png"},"tech_support":{"email":null,"phone":null,"hide_contact":0,"use_email":0,"url":null},"is_member":1,"request":{"id":24879,"uri":"shimamura-y","title":"Shimamura Y","image":{"source":"https:\/\/www.protocols.io\/img\/group_placeholder.png","placeholder":"https:\/\/www.protocols.io\/img\/group_placeholder.png"},"tech_support":{"email":null,"phone":null,"hide_contact":0,"use_email":0,"url":null},"is_member":1,"description":null,"research_interests":null,"website":null,"location":null,"affiliation":null,"status":{"is_visible":true,"access_level":0},"stats":{"files":[],"total_members":0,"total_followers":0,"total_child_groups":0,"total_parent_groups":0,"has_collaborations":0},"user_status":{"is_member":true,"is_confirmed":true,"is_invited":false,"is_owner":true,"is_admin":false,"is_following":false},"join_link":null,"token":null,"owner":{"name":" ","affiliation":null,"affiliations":[],"username":null,"note":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"is_protocol_requested":0,"is_group_requested":0,"is_my":false,"is_request":false,"is_confirmed":1,"is_declined":0,"requester":{"name":" ","affiliation":null,"affiliation_url":null,"username":null,"link":null},"protocol":{"id":0,"title":"Efficacy and safety of endovascular arteriovenous fistula creation with comparison to surgically created fistulas: a systematic review and meta-analysis protocol","title_html":"Efficacy and safety of endovascular arteriovenous fistula creation with comparison to surgically created fistulas: a systematic review and meta-analysis protocol","image":{"source":null,"placeholder":null},"doi":null,"doi_status":0,"uri":"efficacy-and-safety-of-endovascular-arteriovenous-buxwnxpe","type_id":1,"template_id":0,"published_on":null,"stats":{"number_of_views":0,"number_of_steps":0,"number_of_bookmarks":0,"number_of_comments":0,"number_of_exports":0,"number_of_runs":0,"number_of_votes":0,"is_voted":0},"parent_protocols":[],"parent_collections":[],"cited_protocols":[]},"created_on":1620910309,"resolve_on":0,"resolved_user":{"name":" ","affiliation":null,"affiliations":[],"username":null,"note":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"shared":false}}],"is_owner":1,"has_subprotocols":0,"is_subprotocol":0,"is_bookmarked":0,"can_claim_authorship":0,"can_accept_authorship":0,"can_be_copied":1,"can_remove_fork":1,"fork_id":null,"url":"https:\/\/www.protocols.io\/view\/efficacy-and-safety-of-endovascular-arteriovenous-buxwnxpe","forks_count":{"private":0,"public":0},"access":{"can_view":1,"can_remove":0,"can_add":0,"can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":1,"can_move":1,"can_move_outside":1,"can_transfer":1,"can_download":1,"is_locked":0},"guid":"52EBBF30B2D211EB9C18BD972878978D","state_version_id":280,"steps":[{"id":1177412,"guid":"BCB8FCE0B38E11EBA35C592A67433DD8","previous_id":null,"previous_guid":null,"modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"389AD5BC4A1240CE80469C60B31B7B4C","order_id":1,"type_id":6,"title":"Section","source":{"title":"Introduction"}},{"id":1054724,"guid":"B999F98B87704BE891076DBD146262B2","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">Functional vascular access is the lifeline of hemodialysis patients. The Kidney Disease Outcomes Quality Initiative guideline strongly recommends the creation of arteriovenous fistulas for long-term vascular access. Although arteriovenous fistulas have been created using open surgery, endovascular techniques, the Ellipsys Vascular Access System (Avenu Medical, San Juan Capistrano, California) and the everlinQ endovascular arteriovenous fistula system (TVA Medical, Austin, Texas), were approved by the Food and Drug Administration in 2018. <\/div><div class = \"text-block\">A recent meta-analysis of the endovascular devices reported that the 90-day maturation rate and procedure-related complication rate were 97.5 % and 5.46 %, respectively. Despite the comprehensive search, this meta-analysis did not consider patient-centered outcomes such as patient satisfaction, and it did not directly compare endovascular techniques and surgical arteriovenous creation. To the best of our knowledge, there have been no reviews directly comparing endovascular arteriovenous fistula creation and surgical arteriovenous fistula creation to investigate clinically relevant outcomes, including vascular access maturation, complications, and patient satisfaction. <\/div><div class = \"text-block\">This systematic review and meta-analysis aimed to critically evaluate existing evidence on the clinical efficacy and safety of endovascular arteriovenous fistula creation for the management of chronic kidney disease requiring hemodialysis.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#A492FF","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177413,"guid":"D2E31F00B38E11EBA35C592A67433DD8","previous_id":1177413,"previous_guid":"D2E31F00B38E11EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"866F9B851FF04E32BB261D6D1E425E5D","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"7FCCB91125C247D293C7E3B0B6808882","order_id":1,"type_id":1,"title":"Description","source":{"description":""}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177429,"guid":"200B3500B39011EBA35C592A67433DD8","previous_id":1177412,"previous_guid":"BCB8FCE0B38E11EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"5EDAC31BEA3A464C9FF2CFC89B105F5C","order_id":1,"type_id":6,"title":"Section","source":{"title":"Research question"}},{"id":1054724,"guid":"1B71B694F9174637A07863235B578F2C","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">P: Patients with chronic kidney disease<\/div><div class = \"text-block\">I: Endovascular arteriovenous fistula creation<\/div><div class = \"text-block\">C: Surgical arteriovenous fistula creation<\/div><div class = \"text-block\">O: Maturation of fistula, Procedure-related complications, Patient satisfaction<\/div><div class = \"text-block\">The research question addressed in this study is: \u201cDoes endovascular arteriovenous fistula creation have better efficacy and safety, including maturation of fistula, procedure-related complications, and patient satisfaction, compared with surgical arteriovenous fistula creation among patients with chronic kidney disease.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#94EBFF","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177430,"guid":"455A2410B39011EBA35C592A67433DD8","previous_id":1177429,"previous_guid":"200B3500B39011EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"B89A7AB64CC94BBCBEE0F9C571A5E542","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"05B601A4B46D4A519440A78828474993","order_id":1,"type_id":1,"title":"Description","source":{"description":""}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177431,"guid":"4FDC6B00B39011EBA35C592A67433DD8","previous_id":1177430,"previous_guid":"455A2410B39011EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"A18D5ECBD9A340DFB85D94B7B3D0F143","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"58A6C675804F4B6C901F5BB9FC80D02E","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Protocol<\/span><\/div><div class = \"text-block\">We used a systematic review protocol template (<\/div><div class = \"text-block\"><a href=\"https:\/\/dx.doi.org\/10.17504\/protocols.io.biqrkdv6\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">dx.doi.org\/10.17504\/protocols.io.biqrkdv6<\/span><\/a><\/div><div class = \"text-block\"><span>). We followed the Preferred reporting items for systematic review and meta-analysis 2020 (PRISMA-2020) for preparing this protocol.<\/span><span style = \"vertical-align:super;\">1<\/span><span> We will publish this protocol in protocols.io (<\/span><\/div><div class = \"text-block\"><a href=\"https:\/\/www.protocols.io\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">https:\/\/www.protocols.io\/<\/span><\/a><\/div><div class = \"text-block\">).<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177432,"guid":"6C96D960B39011EBA35C592A67433DD8","previous_id":1177431,"previous_guid":"4FDC6B00B39011EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"8AC3169937624CC384DA9DE18B33E383","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"6EE1303C38C7402181E1469E30D037CD","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Inclusion criteria of the articles for the review<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.2.1 Type of studies<\/span><\/div><div class = \"text-block\">We will include randomized controlled, cluster-randomized, quasi-randomized, non-randomized trials, and observational studies that assess theefficacy and safety of endovascular arteriovenous fistula creation. We will not apply language or country restrictions. We will include all papers including published, unpublished articles, abstract of conference, and letter.<\/div><div class = \"text-block\">We will exclude case reports, case series, animal and laboratory studies, and literature reviews. We will not exclude studies based on the observation period or publication year.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.2.2 Study participants<\/span><\/div><div class = \"text-block\">Studies will be included regardless of the etiology of chronic kidney disease, follow-up duration, and country of origin. We will include patients of any age, sex, and race, but exclude those with treatment for dysfunctional hemodialysis arteriovenous fistulas. <\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.2.3 Intervention<\/span><\/div><div class = \"text-block\">Intervention is defined as any percutaneous endovascular approach to creating an arteriovenous fistula, including the Ellipsys Vascular Access System (Avenu Medical, San Juan Capistrano, California), the everlinQ endovascular arteriovenous fistula system (TVA Medical, Austin, Texas), and other devices. We will include studies in which the patients receive the revascularization of arteriovenous fistulas.<\/div><div class = \"text-block\">We will exclude studies in which the patients in the intervention group receive arteriovenous creation other than the upper extremities; however, we will not exclude studies regardless of the methods for anesthesia (general or local) and the expertise and clinical experience of operators. <\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.2.4 Control<\/span><\/div><div class = \"text-block\">Control is defined as any surgical approach to creating an arteriovenous fistula, regardless of the methods and selections of the artery and vein for anastomosis. We will include studies in which the patients receive the placement of arteriovenous grafts or the revascularization of arteriovenous fistulas. We will exclude studies in which the patients receive surgical arteriovenous creation other than the upper extremities; however, we will not exclude studies regardless of the methods for anesthesia (general or local) and the expertise and clinical experience of operators. <\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177434,"guid":"AC0FA0E0B39011EBA35C592A67433DD8","previous_id":1177432,"previous_guid":"6C96D960B39011EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"49DEE706A51C4FF68ECAB367CC3D1F8C","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"5AB576FD0962489EA9CFC08F55BC70D7","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Type of outcomes<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.3.1 Primary outcomes<\/span><\/div><div class = \"text-block\">1. Maturation of fistula<\/div><div class = \"text-block\">Definition: Arteriovenous fistula blood flow of \u2265500 ml per minute and an outflow vein diameter \u22655 mm confirmed by duplex ultrasound or similar definition.<\/div><div class = \"text-block\">Measurement: Incidence proportion of maturation of fistula.<\/div><div class = \"text-block\">Period: The longest follow-up period after arteriovenous fistula creation.<\/div><div class = \"text-block\">2. Procedure-related complications<\/div><div class = \"text-block\">Definition: Definition of adverse events is set by original authors.<\/div><div class = \"text-block\">Measurement: Incidence proportion of procedure-related complications.<\/div><div class = \"text-block\">Period: From the time of procedure initiation to completion.<\/div><div class = \"text-block\">3. Patient satisfaction<\/div><div class = \"text-block\">Definition: Definition of patient satisfaction is set by original authors.<\/div><div class = \"text-block\">Measurement: Measurement of patient satisfaction is set by original authors.<\/div><div class = \"text-block\">Period: At the completion of procedure.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.3.2 Secondary outcomes<\/span><\/div><div class = \"text-block\">1. Procedural technical success<\/div><div class = \"text-block\">Definition: Presence of blood flow in the outflow vein(s) confirmed by duplex ultrasound.<\/div><div class = \"text-block\">Measurement: Incidence proportion of procedural technical success.<\/div><div class = \"text-block\">Period: At the completion of procedure.<\/div><div class = \"text-block\">2. Procedure time<\/div><div class = \"text-block\">Definition: From the time of procedure initiation to completion.<\/div><div class = \"text-block\">Measurement: Minutes.<\/div><div class = \"text-block\">Period: From the time of procedure initiation to completion.<\/div><div class = \"text-block\">3. All adverse events<\/div><div class = \"text-block\">Definition: Definition of adverse events is set by original authors.<\/div><div class = \"text-block\">Measurement: Incidence proportion of all adverse events.<\/div><div class = \"text-block\">Period: during the follow-up period.<\/div><div class = \"text-block\">4. Medical expenditure<\/div><div class = \"text-block\">Definition: Total medical financial cost, including hospitalization, procedure, and materials.<\/div><div class = \"text-block\">Measurement: Reports from medical institutions or patients (US dollar equivalent)<\/div><div class = \"text-block\">Period: From the time of hospital admission to hospital discharge.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177435,"guid":"E89DA480B39011EBA35C592A67433DD8","previous_id":1177434,"previous_guid":"AC0FA0E0B39011EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"DA7DDBF9AEEC4872A3F27FD39555731B","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"5074E1645F424BD79BA8D39E50AB75C1","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Search method<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.4.1 Electronic search<\/span><\/div><div class = \"text-block\">We will search the following databases:<\/div><div class = \"text-block\">1. MEDLINE (PubMed);<\/div><div class = \"text-block\">2. the Cochrane Central Register of Controlled Trials (Cochrane Library);<\/div><div class = \"text-block\">3. EMBASE (Dialog);<\/div><div class = \"text-block\">See Appendix 1, 2, and 3 for the search strategies.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.4.2 Other resources<\/span><\/div><div class = \"text-block\">We will also search the following databases for ongoing or unpublished trials:<\/div><div class = \"text-block\">1. the World Health Organization International Clinical Trials Platform Search Portal (ICTRP);<\/div><div class = \"text-block\">2. ClinicalTrials.gov;<\/div><div class = \"text-block\">See Appendix 4, 5 for the search strategies.<\/div><div class = \"text-block\">We will check the reference lists of studies, including international guidelines (KDOQI clinical practice guideline for vascular access: 2019 update) as well as the reference lists of eligible studies and articles citing eligible studies. We will ask the authors of original studies for unpublished or additional data.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177436,"guid":"F712F790B39011EBA35C592A67433DD8","previous_id":1177435,"previous_guid":"E89DA480B39011EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"60BDE5F73CE84A37A9B04ABF0A8E1410","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"79404E1C6D944C58B975D704F8504A8F","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Data collection and analysis<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.5.1 Selection of the studies<\/span><\/div><div class = \"text-block\">Two independent reviewers (YS and HY) will screen titles and abstracts, followed by the assessment of the eligibility based on the full texts. We will contact the original authors if relevant data is missing. Disagreements between the two reviewers will be resolved by discussion, and if this fails, a third reviewer will act as an arbiter (YT or YK).<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.5.2 Data extraction and management<\/span><\/div><div class = \"text-block\">Two reviewers (YS and HY) will perform independent data extraction of the included studies using a standardized data collection form. We will use a pre-checked form using 10 randomly selected studies. <\/div><div class = \"text-block\">The form will include the information on study design, study population, interventions, unadjusted and adjusted effect estimates, and outcomes. Any disagreements will be resolved by discussion, and if this fails, a third reviewer will act as an arbiter (YT or YK). <\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177437,"guid":"0A0F8070B39111EBA35C592A67433DD8","previous_id":1177436,"previous_guid":"F712F790B39011EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"38D70C269FD145278C45BC01A8C9AECD","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"640599C0DF6B4C81B3161CD5896EE6AA","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Assessment of risk of bias in included studies<\/span><\/div><div class = \"text-block\"><span>Two reviewers (YS and HY) will evaluate the risk of bias independently using theROBINS-I.<\/span><span style = \"vertical-align:super;\">2<\/span><span> Disagreements between the two reviewers will be discussed, and if this fails, a third reviewer (YT or YK) will be acting as an arbiter, if necessary.<\/span><\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177438,"guid":"1437C080B39111EBA35C592A67433DD8","previous_id":1177437,"previous_guid":"0A0F8070B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"7F7D76AF81C9451E828BE7A9FF3972F8","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"7FDBB6F7857742FE844F70AEEDEBEFCF","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Measures of treatment effects<\/span><\/div><div class = \"text-block\">We will pool the odds ratios and the 95% confidence intervals (CIs) for the following binary variables: Maturation of fistula, Procedure-related complications, Procedural technical success.<\/div><div class = \"text-block\"><span>If adjusted ORs and 95% CIs of the outcomes are not available and if the RRs are reported in primary studies, we will use a method reported by Zhang<\/span><span style = \"vertical-align:super;\">7<\/span><span>et al. to transform RRs into ORs.  If only the HRs were reported, we will contact the authors to confirm the ORs and\/or RRs. If ORs are not available after querying the authors, we will integrate them with ORs and HRs, respectively.<\/span><\/div><div class = \"text-block\">We will pool the mean differences and the 95% CIs for the following continuous variables: Patient satisfaction, Procedure time, and Medical expenditure.<\/div><div class = \"text-block\">If several different scales have been used in the included studies, we will pool the effect estimates using standard mean differences (SMDs)<\/div><div class = \"text-block\">We will summarize adverse events based on the definition by the original article, but we will not perform the meta-analysis.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177439,"guid":"2652C300B39111EBA35C592A67433DD8","previous_id":1177438,"previous_guid":"1437C080B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"A4AB60ED70964DADAF7EF35E101B1DA0","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"45AFA5BD80584DD58D3B72C758369739","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Unit of analysis issues<\/span><\/div><div class = \"text-block\">Clustering at the level of the enrolled units in cluster randomized studies <\/div><div class = \"text-block\"><span>In dealing with cluster-RCTs, for dichotomous data, we will apply the design effect and calculate effective sample size and number of events using the intra-cluster correlation coefficient (ICC) among each unit and the average cluster size, as described in Chapter 16.3.5 of the Cochrane Handbook.<\/span><span style = \"vertical-align:super;\">3<\/span><span> If the ICC has not been reported, we will use the ICC of a similar study as a substitute. For continuous data, only the sample size will be reduced; means and standard deviation will remain unchanged. <\/span><span style = \"vertical-align:super;\">3<\/span><\/div><div class = \"text-block\">Multiple comparisons<\/div><div class = \"text-block\">All intervention groups that are relevant to this review will be included.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177440,"guid":"38352950B39111EBA35C592A67433DD8","previous_id":1177439,"previous_guid":"2652C300B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"AE6D9C83B47840DDA1631F8F43BE07E9","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"73601D06CC0F4E389FDED86A57C5CFB7","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Handling of missing data<\/span><\/div><div class = \"text-block\">We will ask for not-presented data from the original authors.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.9.1 Missing outcomes<\/span><\/div><div class = \"text-block\">We will analyze the data on the intention-to-treat (ITT) basis. If there is missing data that should be available but not presented in the publications, we will seek further information directly from the authors of the studies and will analyze only the available data if no additional information is forthcoming. Any imputation of the outcome data by the original investigators will be critically appraised through the risk of bias assessment. <\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.9.2 Missing statistics<\/span><\/div><div class = \"text-block\"><span>When original studies only report standard error or p-value for continuous outcomes, we will calculate the standard deviation based on the method by Altman.<\/span><span style = \"vertical-align:super;\">4<\/span><span> If we don't know these values when we contact the authors, standard deviation will be calculated by confidence interval and t-value based on the method by Cochrane handbook<\/span><span style = \"vertical-align:super;\">3<\/span><span>, or validated method.<\/span><span style = \"vertical-align:super;\">5<\/span><span> Validity of these methods will be analyzed by sensitivity analysis.<\/span><\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177441,"guid":"4E620A90B39111EBA35C592A67433DD8","previous_id":1177440,"previous_guid":"38352950B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"6FBAC4A6D8F340719C74A976122DAADB","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"823916230B6E452C94E538CBDC1B7405","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Assessment of heterogeneity<\/span><\/div><div class = \"text-block\">We will evaluate the statistical heterogeneity by visual inspection of the forest plots and calculating the I2 statistic (I2 values of 0% to 40%: might not be important; 30%to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity). Cochrane Chi2test (Q-test) will be performed for I2 statistic, and P value less than 0.10 will be defined as statistically significant.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177442,"guid":"5A109C80B39111EBA35C592A67433DD8","previous_id":1177441,"previous_guid":"4E620A90B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"2C43224641B04C1184AD0DA521AB1B33","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"AB3C3730B6064BA8A863DE833CD2400A","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Assessment of reporting bias<\/span><\/div><div class = \"text-block\">We will search the clinical trial registry system (ClinicalTrials.gov and ICTRP) and will perform extensive literature search for unpublished trials. To assess outcome reporting bias, we will compare the outcomes defined in trial protocols with the outcomes reported in the publications. We will assess the potential publication bias by visual inspection of the funnel plot. We will conduct Egger test to assess the publication bias. We will not conduct the test when we find less than 10 trials or trials that have similar sample sizes. We will also assess the potential publication bias by visual inspection of the funnel plot.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177443,"guid":"76C146E0B39111EBA35C592A67433DD8","previous_id":1177442,"previous_guid":"5A109C80B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"7792BD79DBB44113BA616DD1E0C34BC5","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"DA34987133E143409AB5BFA4DD564738","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Meta-analysis<\/span><\/div><div class = \"text-block\">Meta-analysis will be performed using Review Manager software (RevMan 5.4.2). We will use a random-effects model. We will prioritize the adjusted effect estimates if we extract data from observational studies.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177444,"guid":"807BA9F0B39111EBA35C592A67433DD8","previous_id":1177443,"previous_guid":"76C146E0B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"38230D5ED42145C09A21421A09E39CB1","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"5CEAB4FEEB464D9291078F05D43FB2E2","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Subgroup analysis<\/span><\/div><div class = \"text-block\">To elucidate the influence of effect modifiers on results, we will evaluate the subgroup analyses of the primary outcomes on the following factors when sufficient data are available.<\/div><div class = \"text-block\">1. Patients with diabetic nephropathy versus those with non-diabetic nephropathy. <\/div><div class = \"text-block\">2. Ellipsys Vascular Access System versus everlinQ endovascular arteriovenous fistula system.<\/div><div class = \"text-block\">3. Surgical arteriovenous fistula using native arteries and veins versus surgical placement of arteriovenous grafts.<\/div><div class = \"text-block\">4. Randomized clinical trials versus non-randomized studies.<\/div><div class = \"text-block\">5. Patients who received the first arteriovenous fistula creation versus patients who received the revascularization of arteriovenous fistulas.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177445,"guid":"8AAFF7F0B39111EBA35C592A67433DD8","previous_id":1177444,"previous_guid":"807BA9F0B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"A1D1ED3DC00A404A9CDA24613F2F4592","order_id":1,"type_id":6,"title":"Section","source":{"title":"Method"}},{"id":1054724,"guid":"1E6DC173C65E485C961FB5959C8F7929","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Sensitivity analysis<\/span><\/div><div class = \"text-block\">We will undertake the following sensitivity analyses for the primary outcomes to assess whether the results of the review are robust to the decisions made during the review process. <\/div><div class = \"text-block\"><ol style = \"list-style-type: decimal;\"><li style = \"counter-reset:ol0;\">Exclusion of studies using imputed statistics.<\/li><li style = \"counter-reset:ol0;\">Inclusion of studies with complete case data<\/li><\/ol><\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177447,"guid":"B3812FF0B39111EBA35C592A67433DD8","previous_id":1177445,"previous_guid":"8AAFF7F0B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"51BCFDA1E4ED4312960325378A9C1694","order_id":1,"type_id":6,"title":"Section","source":{"title":"Summary of findings table"}},{"id":1054724,"guid":"C087583378F5406EA9E8FDE402404E52","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span>Two reviewers (YS and YT) will evaluate the certainty of evidence based on the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.<\/span><span style = \"vertical-align:super;\">6<\/span><span>Disagreements between the two reviewers will be discussed, and if this fails, a third reviewer (YK) will be acting as an arbiter, if necessary.<\/span><\/div><div class = \"text-block\"><span>Summary of findings table will be made for the following outcome based on the Cochrane handbook.<\/span><span style = \"vertical-align:super;\">3<\/span><\/div><div class = \"text-block\">1. Maturation of fistula<\/div><div class = \"text-block\">2. Procedure-related complications<\/div><div class = \"text-block\">3. Patient satisfaction<\/div><div class = \"text-block\">4. Procedural technical success<\/div><div class = \"text-block\">5. Procedure time<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#FFED92","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177449,"guid":"E8221670B39111EBA35C592A67433DD8","previous_id":1177447,"previous_guid":"B3812FF0B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"54CE2F034EAC409B86A996CBAEE43C23","order_id":1,"type_id":6,"title":"Section","source":{"title":"Conflict of Interest"}},{"id":1054724,"guid":"FD07D8FC61EA4DEE9376727C1680CA6D","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">The authors declare no conflicts of interest.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#EA9F6C","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1177450,"guid":"FEFAA100B39111EBA35C592A67433DD8","previous_id":1177449,"previous_guid":"E8221670B39111EBA35C592A67433DD8","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"E38E49D1F9C24FAEA22A34ABA03345F1","order_id":1,"type_id":6,"title":"Section","source":{"title":"Support"}},{"id":1054724,"guid":"CCDE402F04134EFF8A37A144722A3587","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">Self-funding.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#E57785","section_duration":0,"critical":null,"critical_id":null,"duration":0}],"document":"","materials":[],"description":"<div class = \"text-blocks\"><div class = \"text-block\">Functional vascular access is the lifeline of hemodialysis patients. The Kidney Disease Outcomes Quality Initiative guideline strongly recommends the creation of arteriovenous fistulas for long-term vascular access. Although arteriovenous fistulas have been created using open surgery, endovascular techniques, the Ellipsys Vascular Access System (Avenu Medical, San Juan Capistrano, California) and the everlinQ endovascular arteriovenous fistula system (TVA Medical, Austin, Texas), were approved by the Food and Drug Administration in 2018. <\/div><div class = \"text-block\">A recent meta-analysis of the endovascular devices reported that the 90-day maturation rate and procedure-related complication rate were 97.5 % and 5.46 %, respectively. Despite the comprehensive search, this meta-analysis did not consider patient-centered outcomes such as patient satisfaction, and it did not directly compare endovascular techniques and surgical arteriovenous creation. To the best of our knowledge, there have been no reviews directly comparing endovascular arteriovenous fistula creation and surgical arteriovenous fistula creation to investigate clinically relevant outcomes, including vascular access maturation, complications, and patient satisfaction. <\/div><div class = \"text-block\">This systematic review and meta-analysis aimed to critically evaluate existing evidence on the clinical efficacy and safety of endovascular arteriovenous fistula creation for the management of chronic kidney disease requiring hemodialysis.<\/div><\/div>","changed_on":1620910302}